Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Faron Pharmaceuticals Oy ( (GB:FARN) ) has provided an announcement.
Faron Pharmaceuticals said its Non-Executive Chairman, Tuomo Pätsi, has subscribed for 400,002 new ordinary shares at €0.50 each under the company’s ongoing rights issue launched on 10 March 2026. The insider participation underscores board-level support for the capital raise, which is expected to strengthen Faron’s financial position as it advances development of its lead cancer immunotherapy bexmarilimab.
Bexmarilimab is designed to bind the Clever-1 receptor on macrophages and shift them from an immunosuppressive to an immunostimulatory state, potentially enhancing patients’ responses to existing cancer treatments. The transaction disclosure, made under EU market abuse regulations, may reassure investors about management’s confidence in the company’s strategy and prospects in the competitive oncology immunotherapy space.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd is a Turku-based, clinical-stage biopharmaceutical company listed on AIM and Nasdaq First North, focused on developing novel immunotherapies to treat cancers. Its lead asset, bexmarilimab, is a wholly owned anti-Clever-1 humanized antibody designed to reprogram immunosuppressive myeloid cells and is currently being investigated in Phase I/II trials for hematological malignancies in combination with standard treatments.
See more insights into FARN stock on TipRanks’ Stock Analysis page.